Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Breast Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 148 articles:
HTML format



Single Articles


    June 2020
  1. PARK SA, Sung NJ, Choi BJ, Kim W, et al
    Gremlin-1 augments the oestrogen-related receptor alpha signalling through EGFR activation: implications for the progression of breast cancer.
    Br J Cancer. 2020 Jun 23. pii: 10.1038/s41416-020-0945.
    PubMed     Abstract available


  2. MING C, Viassolo V, Probst-Hensch N, Dinov ID, et al
    Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations.
    Br J Cancer. 2020 Jun 22. pii: 10.1038/s41416-020-0937.
    PubMed     Abstract available


  3. MESA-EGUIAGARAY I, Wild SH, Rosenberg PS, Bird SM, et al
    Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data.
    Br J Cancer. 2020 Jun 19. pii: 10.1038/s41416-020-0938.
    PubMed     Abstract available


  4. ROBERTO A, Colombo C, Candiani G, Satolli R, et al
    A dynamic web-based decision aid to improve informed choice in organised breast cancer screening. A pragmatic randomised trial in Italy.
    Br J Cancer. 2020 Jun 17. pii: 10.1038/s41416-020-0935.
    PubMed     Abstract available


  5. YUAN WH, Hsu HC, Chen YY, Wu CH, et al
    Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis.
    Br J Cancer. 2020 Jun 12. pii: 10.1038/s41416-020-0928.
    PubMed     Abstract available


  6. WAN G, Zhu J, Gu X, Yang Y, et al
    Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription.
    Br J Cancer. 2020 Jun 3. pii: 10.1038/s41416-020-0873.
    PubMed     Abstract available


  7. KOUTRAS A, Zagouri F, Koliou GA, Psoma E, et al
    Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial.
    Br J Cancer. 2020 Jun 3. pii: 10.1038/s41416-020-0909.
    PubMed     Abstract available


    May 2020
  8. TANG M, Schaffer A, Kiely BE, Daniels B, et al
    Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
    Br J Cancer. 2020 May 29. pii: 10.1038/s41416-020-0908.
    PubMed     Abstract available


  9. CHEUNG SM, Husain E, Masannat Y, Miller ID, et al
    Lactate concentration in breast cancer using advanced magnetic resonance spectroscopy.
    Br J Cancer. 2020 May 19. pii: 10.1038/s41416-020-0886.
    PubMed     Abstract available


  10. ORLANDELLA FM, Mariniello RM, Mirabelli P, De Stefano AE, et al
    miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase.
    Br J Cancer. 2020 May 18. pii: 10.1038/s41416-020-0884.
    PubMed     Abstract available


  11. LAMEIJER JRC, Voogd AC, Pijnappel RM, Setz-Pels W, et al
    Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: an observational follow-up study from the Netherlands.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0870.
    PubMed     Abstract available


  12. EGGEMANN H, Brucker C, Schrauder M, Thill M, et al
    Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis.
    Br J Cancer. 2020 May 5. pii: 10.1038/s41416-020-0857.
    PubMed     Abstract available


    April 2020
  13. JAHN SW, Bosl A, Tsybrovskyy O, Gruber-Rossipal C, et al
    Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0838.
    PubMed     Abstract available


  14. MUKAI H, Yamaguchi T, Takahashi M, Hozumi Y, et al
    Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
    Br J Cancer. 2020 Apr 2. pii: 10.1038/s41416-020-0815.
    PubMed     Abstract available


    March 2020
  15. BLONDEAUX E, Lambertini M, Michelotti A, Conte B, et al
    Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study.
    Br J Cancer. 2020 Mar 31. pii: 10.1038/s41416-020-0816.
    PubMed     Abstract available


  16. MCKENZIE HS, Maishman T, Simmonds P, Durcan L, et al
    Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients.
    Br J Cancer. 2020 Mar 31. pii: 10.1038/s41416-020-0784.
    PubMed     Abstract available


  17. RENEHAN AG, Pegington M, Harvie MN, Sperrin M, et al
    Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom).
    Br J Cancer. 2020 Mar 23. pii: 10.1038/s41416-020-0807.
    PubMed     Abstract available


  18. EIGER D, Ponde NF, Agbor-Tarh D, Moreno-Aspitia A, et al
    Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
    Br J Cancer. 2020 Mar 16. pii: 10.1038/s41416-020-0786.
    PubMed     Abstract available


    February 2020
  19. WONG EM, Southey MC, Terry MB
    Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-019-0720.
    PubMed     Abstract available


  20. BENS A, Dehlendorff C, Friis S, Cronin-Fenton D, et al
    The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study.
    Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0747.
    PubMed     Abstract available


  21. VARIKUTI S, Singh B, Volpedo G, Ahirwar DK, et al
    Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
    Br J Cancer. 2020 Feb 6. pii: 10.1038/s41416-020-0743.
    PubMed     Abstract available


    January 2020
  22. LEREBOURS F, Pulido M, Fourme E, Debled M, et al
    Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
    Br J Cancer. 2020 Jan 31. pii: 10.1038/s41416-020-0733.
    PubMed     Abstract available


  23. FARHAT D, Leon S, Ghayad SE, Gadot N, et al
    Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation.
    Br J Cancer. 2020 Jan 28. pii: 10.1038/s41416-020-0729.
    PubMed     Abstract available


  24. CASCIANO JC, Perry C, Cohen-Nowak AJ, Miller KD, et al
    MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer.
    Br J Cancer. 2020 Jan 16. pii: 10.1038/s41416-019-0711.
    PubMed     Abstract available


  25. MULL BB, Livingston JA, Patel N, Bui T, et al
    Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer.
    Br J Cancer. 2020 Jan 16. pii: 10.1038/s41416-019-0707.
    PubMed     Abstract available


  26. RIBI K, Luo W, Colleoni M, Karlsson P, et al
    Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
    Br J Cancer. 2020 Jan 16. pii: 10.1038/s41416-019-0709.
    PubMed     Abstract available


  27. HARVIE M, Pegington M, Bundred N, Campbell A, et al
    Reply to Comment on "The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial".
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0715.
    PubMed    


  28. BAIL JR, Halilova KI, Demark-Wahnefried W, Reeves MM, et al
    Comment on "The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial".
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0714.
    PubMed    


  29. AHN S, Kim HJ, Kang E, Kim EK, et al
    Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity.
    Br J Cancer. 2020 Jan 13. pii: 10.1038/s41416-019-0713.
    PubMed     Abstract available


  30. GUO W, Fensom GK, Reeves GK, Key TJ, et al
    Physical activity and breast cancer risk: results from the UK Biobank prospective cohort.
    Br J Cancer. 2020 Jan 10. pii: 10.1038/s41416-019-0700.
    PubMed     Abstract available


    December 2019
  31. HUNTER FW, Barker HR, Lipert B, Rothe F, et al
    Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
    Br J Cancer. 2019 Dec 16. pii: 10.1038/s41416-019-0635.
    PubMed     Abstract available


  32. LORD SR, Collins JM, Cheng WC, Haider S, et al
    Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0665.
    PubMed     Abstract available


  33. KAWASHIMA M, Tokiwa M, Nishimura T, Kawata Y, et al
    High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0662.
    PubMed     Abstract available


  34. SOLA-PENNA M, Paixao LP, Branco JR, Ochioni AC, et al
    Serotonin activates glycolysis and mitochondria biogenesis in human breast cancer cells through activation of the Jak1/STAT3/ERK1/2 and adenylate cyclase/PKA, respectively.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0640.
    PubMed     Abstract available


  35. ANSARI RE, Craze ML, Althobiti M, Alfarsi L, et al
    Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0626.
    PubMed     Abstract available


  36. HO-PUN-CHEUNG A, Bazin H, Boissiere-Michot F, Mollevi C, et al
    Quantification of HER1, HER2 and HER3 by time-resolved Forster resonance energy transfer in FFPE triple-negative breast cancer samples.
    Br J Cancer. 2019 Dec 3. pii: 10.1038/s41416-019-0670.
    PubMed     Abstract available


    November 2019
  37. NICOUD MB, Sterle HA, Massari NA, Taquez Delgado MA, et al
    Study of the antitumour effects and the modulation of immune response by histamine in breast cancer.
    Br J Cancer. 2019 Nov 21. pii: 10.1038/s41416-019-0636.
    PubMed     Abstract available


  38. WITZEL I, Loibl S, Wirtz R, Fasching PA, et al
    Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.
    Br J Cancer. 2019 Nov 15. pii: 10.1038/s41416-019-0630.
    PubMed     Abstract available


  39. DARLIX A, Louvel G, Fraisse J, Jacot W, et al
    Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
    Br J Cancer. 2019 Nov 13. pii: 10.1038/s41416-019-0619.
    PubMed     Abstract available


  40. XUE Y, Lian W, Zhi J, Yang W, et al
    HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer.
    Br J Cancer. 2019 Nov 6. pii: 10.1038/s41416-019-0625.
    PubMed     Abstract available


  41. SIM SH, Park IH, Jung KH, Kim SB, et al
    Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).
    Br J Cancer. 2019 Nov 6. pii: 10.1038/s41416-019-0618.
    PubMed     Abstract available


  42. TANG M, Schaffer A, Kiely BE, Daniels B, et al
    Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
    Br J Cancer. 2019 Nov 1. pii: 10.1038/s41416-019-0612.
    PubMed     Abstract available


    September 2019
  43. JOSEPH C, Al-Izzi S, Alsaleem M, Kurozumi S, et al
    Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
    Br J Cancer. 2019 Sep 27. pii: 10.1038/s41416-019-0589.
    PubMed     Abstract available


  44. MUNZONE E, Pagan E, Bagnardi V, Mazzocco K, et al
    Reply to Comments on: "Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines."
    Br J Cancer. 2019 Sep 17. pii: 10.1038/s41416-019-0577.
    PubMed    


  45. KAKO J, Kajiwara K, Kobayashi M, Oosono Y, et al
    Comment on: "Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines".
    Br J Cancer. 2019 Sep 17. pii: 10.1038/s41416-019-0576.
    PubMed    


  46. SAFI N, Anazodo A, Dickinson JE, Lui K, et al
    In utero exposure to breast cancer treatment: a population-based perinatal outcome study.
    Br J Cancer. 2019 Sep 6. pii: 10.1038/s41416-019-0563.
    PubMed     Abstract available


  47. JONES ME, Schoemaker MJ, McFadden EC, Wright LB, et al
    Reply to Comment on: "Night shift work and risk of breast cancer in women: the Generations Study cohort".
    Br J Cancer. 2019 Sep 5. pii: 10.1038/s41416-019-0568.
    PubMed    


  48. KOGEVINAS M
    Comment on: "Night shift work and risk of breast cancer in women: the Generations Study cohort".
    Br J Cancer. 2019 Sep 5. pii: 10.1038/s41416-019-0567.
    PubMed    


  49. CHATTERJEE A, Jana S, Chatterjee S, Wastall LM, et al
    MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer.
    Br J Cancer. 2019 Sep 4. pii: 10.1038/s41416-019-0566.
    PubMed     Abstract available


    August 2019
  50. BHATTARAI S, Klimov S, Aleskandarany MA, Burrell H, et al
    Machine learning-based prediction of breast cancer growth rate in vivo.
    Br J Cancer. 2019 Aug 9. pii: 10.1038/s41416-019-0539.
    PubMed     Abstract available


  51. HARVIE M, Pegington M, McMullan D, Bundred N, et al
    The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.
    Br J Cancer. 2019 Aug 1. pii: 10.1038/s41416-019-0522.
    PubMed     Abstract available


    July 2019
  52. MUNZONE E, Bagnardi V, Campenni G, Mazzocco K, et al
    Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines.
    Br J Cancer. 2019 Jul 15. pii: 10.1038/s41416-019-0520.
    PubMed     Abstract available


  53. LEE DW, Ryu HS, Jin MS, Lee KH, et al
    Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients.
    Br J Cancer. 2019 Jul 11. pii: 10.1038/s41416-019-0511.
    PubMed     Abstract available


    June 2019
  54. CAPULLI M, Hristova D, Valbret Z, Carys K, et al
    Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry.
    Br J Cancer. 2019 Jun 26. pii: 10.1038/s41416-019-0501.
    PubMed     Abstract available


    May 2019
  55. JONES ME, Schoemaker MJ, McFadden EC, Wright LB, et al
    Night shift work and risk of breast cancer in women: the Generations Study cohort.
    Br J Cancer. 2019 May 29. pii: 10.1038/s41416-019-0485.
    PubMed     Abstract available


  56. KUROZUMI S, Joseph C, Sonbul S, Alsaeed S, et al
    A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.
    Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0486.
    PubMed     Abstract available


  57. LOURO J, Posso M, Hilton Boon M, Roman M, et al
    A systematic review and quality assessment of individualised breast cancer risk prediction models.
    Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0476.
    PubMed     Abstract available


  58. LIM B, Murthy RK, Lee J, Jackson SA, et al
    A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
    Br J Cancer. 2019 May 17. pii: 10.1038/s41416-019-0473.
    PubMed     Abstract available


    April 2019
  59. DAULAT AM, Finetti P, Revinski D, Silveira Wagner M, et al
    ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.
    Br J Cancer. 2019 Apr 11. pii: 10.1038/s41416-019-0448.
    PubMed     Abstract available


  60. RIBI K, Luo W, Colleoni M, Karlsson P, et al
    Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
    Br J Cancer. 2019 Apr 10. pii: 10.1038/s41416-019-0435.
    PubMed     Abstract available


    February 2019
  61. ABDEL-FATAH TMA, Broom RJ, Lu J, Moseley PM, et al
    SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
    Br J Cancer. 2019 Feb 28. pii: 10.1038/s41416-019-0405.
    PubMed     Abstract available


  62. LI N, Kong J, Lin Z, Yang Y, et al
    Ezrin promotes breast cancer progression by modulating AKT signals.
    Br J Cancer. 2019 Feb 26. pii: 10.1038/s41416-019-0383.
    PubMed     Abstract available


  63. MEJDAHL MK, Wohlfahrt J, Holm M, Balslev E, et al
    Breast cancer mortality in synchronous bilateral breast cancer patients.
    Br J Cancer. 2019 Feb 26. pii: 10.1038/s41416-019-0403.
    PubMed     Abstract available


  64. ESCALA-GARCIA M, Guo Q, Dork T, Canisius S, et al
    Genome-wide association study of germline variants and breast cancer-specific mortality.
    Br J Cancer. 2019 Feb 21. pii: 10.1038/s41416-019-0393.
    PubMed     Abstract available


  65. MILEVSKIY MJG, Gujral U, Del Lama Marques C, Stone A, et al
    MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer.
    Br J Cancer. 2019 Feb 20. pii: 10.1038/s41416-019-0395.
    PubMed     Abstract available


  66. FUJIWARA Y, Mukai H, Saeki T, Ro J, et al
    A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
    Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-019-0391.
    PubMed     Abstract available


  67. METCALFE K, Lynch HT, Foulkes WD, Tung N, et al
    Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
    Br J Cancer. 2019 Feb 6. pii: 10.1038/s41416-019-0376.
    PubMed     Abstract available


    January 2019
  68. OWEN LJ, Monaghan PJ, Armstrong A, Keevil BG, et al
    Oestradiol measurement during fulvestrant treatment for breast cancer.
    Br J Cancer. 2019 Jan 25. pii: 10.1038/s41416-019-0378.
    PubMed     Abstract available


  69. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Abstract available


  70. EGGEMANN H, Bernreiter AL, Reinisch M, Loibl S, et al
    Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0369.
    PubMed     Abstract available


    December 2018
  71. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 Dec 25. pii: 10.1038/s41416-018-0344.
    PubMed    


  72. KYBA CCM, Spitschan M
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study'.
    Br J Cancer. 2018 Dec 25. pii: 10.1038/s41416-018-0203.
    PubMed    


  73. PEGRAM MD, Bondarenko I, Zorzetto MMC, Hingmire S, et al
    PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
    Br J Cancer. 2018 Dec 20. pii: 10.1038/s41416-018-0340.
    PubMed     Abstract available


  74. ROMAN M, Hofvind S, von Euler-Chelpin M, Castells X, et al
    Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts.
    Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0358.
    PubMed     Abstract available


  75. LOPEZ-KNOWLES E, Pearson A, Schuster G, Gellert P, et al
    Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
    Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0345.
    PubMed     Abstract available


    November 2018
  76. TIAN J, Raffa FA, Dai M, Moamer A, et al
    Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0287.
    PubMed     Abstract available


  77. GIANNAKEAS V, Cadarette SM, Ban JK, Lipscombe L, et al
    Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0225.
    PubMed     Abstract available


  78. SNELL CE, Gough M, Liu C, Middleton K, et al
    Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-alpha and progesterone receptor-b.
    Br J Cancer. 2018 Nov 9. pii: 10.1038/s41416-018-0331.
    PubMed     Abstract available


    October 2018
  79. MCGREGOR RJ, Chau YY, Kendall TJ, Artibani M, et al
    WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer.
    Br J Cancer. 2018 Oct 30. pii: 10.1038/s41416-018-0317.
    PubMed     Abstract available


  80. MUNSTER P, Krop IE, LoRusso P, Ma C, et al
    Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
    Br J Cancer. 2018 Oct 26. pii: 10.1038/s41416-018-0235.
    PubMed     Abstract available


  81. TAMBOUR M, Holt M, Speyer A, Christensen R, et al
    Manual lymphatic drainage adds no further volume reduction to Complete Decongestive Therapy on breast cancer-related lymphoedema: a multicentre, randomised, single-blind trial.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0306.
    PubMed     Abstract available


  82. BERTUCCI F, Finetti P, Simeone I, Hendrickx W, et al
    The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0309.
    PubMed     Abstract available


  83. LANGBALLE R, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Statin use and risk of contralateral breast cancer: a nationwide cohort study.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0252.
    PubMed     Abstract available


  84. WALASZEK K, Lower EE, Ziolkowski P, Weber GF, et al
    Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0228.
    PubMed     Abstract available


  85. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0177.
    PubMed    


  86. SCIMECA M, Urbano N, Bonfiglio R, Schillaci O, et al
    Breast osteoblast-like cells: a new biomarker for the management of breast cancer.
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0255.
    PubMed     Abstract available


  87. MEURS CJC, van Rosmalen J, Menke-Pluijmers MBE, Ter Braak BPM, et al
    A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers.
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0276.
    PubMed     Abstract available


  88. CHAKRABORTY S, Jiang C, Gau D, Oddo M, et al
    Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0284.
    PubMed     Abstract available


  89. O'CARRIGAN B, Lim JSJ, Jalil A, Harris SJ, et al
    Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0290.
    PubMed     Abstract available


  90. BAJOR M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, et al
    Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0263.
    PubMed     Abstract available


  91. KRUGER DT, Beelen KJ, Opdam M, Sanders J, et al
    Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0221.
    PubMed     Abstract available


  92. STEVENS RG
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 Oct 3. pii: 10.1038/s41416-018-0058.
    PubMed    


  93. BECKWITT CH, Clark AM, Ma B, Whaley D, et al
    Statins attenuate outgrowth of breast cancer metastases.
    Br J Cancer. 2018;119:1094-1105.
    PubMed     Abstract available


  94. MADSSEN TS, Thune I, Flote VG, Lundgren S, et al
    Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment.
    Br J Cancer. 2018;119:1144-1154.
    PubMed     Abstract available


    September 2018
  95. GRAY E, Marti J, Brewster DH, Wyatt JC, et al
    Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data.
    Br J Cancer. 2018 Sep 17. pii: 10.1038/s41416-018-0256.
    PubMed     Abstract available


    August 2018
  96. BOEKEL NB, Jacobse JN, Schaapveld M, Hooning MJ, et al
    Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.
    Br J Cancer. 2018 Aug 1. pii: 10.1038/s41416-018-0159.
    PubMed     Abstract available


    July 2018
  97. SAHA A, Harowicz MR, Grimm LJ, Kim CE, et al
    A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0185.
    PubMed     Abstract available


  98. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
    Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0197.
    PubMed     Abstract available


  99. LAMMERS PE, Dank M, Masetti R, Abbas R, et al
    Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.
    Br J Cancer. 2018 Jul 13. pii: 10.1038/s41416-018-0147.
    PubMed     Abstract available


  100. STERLE HA, Nicoud MB, Massari NA, Taquez Delgado MA, et al
    Immunomodulatory role of histamine H4 receptor in breast cancer.
    Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0173.
    PubMed     Abstract available


    June 2018
  101. LO LL, Milne RL, Liao Y, Cuzick J, et al
    Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.
    Br J Cancer. 2018 Jun 21. pii: 10.1038/s41416-018-0120.
    PubMed     Abstract available


  102. CHERIYATH V, Kaur J, Davenport A, Khalel A, et al
    G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0137.
    PubMed     Abstract available


  103. GUIU S, Mollevi C, Charon-Barra C, Boissiere F, et al
    Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
    Br J Cancer. 2018 Jun 8. pii: 10.1038/s41416-018-0142.
    PubMed     Abstract available


  104. DERKS MGM, Bastiaannet E, Kiderlen M, Hilling DE, et al
    Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group.
    Br J Cancer. 2018 Jun 7. pii: 10.1038/s41416-018-0090.
    PubMed     Abstract available


  105. ROHAN TE, Miller CA, Li T, Wang Y, et al
    Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0089.
    PubMed     Abstract available


  106. TUNG NM, Garber JE
    BRCA1/2 testing: therapeutic implications for breast cancer management.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
    PubMed     Abstract available


  107. HALKETT G, O'Connor M, Jefford M, Aranda S, et al
    RT Prepare: a radiation therapist-delivered intervention reduces psychological distress in women with breast cancer referred for radiotherapy.
    Br J Cancer. 2018 Jun 1. pii: 10.1038/s41416-018-0112.
    PubMed     Abstract available


    May 2018
  108. WEIN L, Luen SJ, Savas P, Salgado R, et al
    Checkpoint blockade in the treatment of breast cancer: current status and future directions.
    Br J Cancer. 2018 May 29. pii: 10.1038/s41416-018-0126.
    PubMed     Abstract available


  109. GULLO G, Walsh N, Fennelly D, Bose R, et al
    Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
    Br J Cancer. 2018 May 18. pii: 10.1038/s41416-018-0114.
    PubMed     Abstract available


  110. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0092.
    PubMed    


  111. MORTAZAVI SMJ
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0060.
    PubMed    


  112. FRENCH DP, Southworth J, Howell A, Harvie M, et al
    Psychological impact of providing women with personalised 10-year breast cancer risk estimates.
    Br J Cancer. 2018 May 8. pii: 10.1038/s41416-018-0069.
    PubMed     Abstract available


  113. CHEN S, Wang H, Li Z, You J, et al
    Interaction of WBP2 with ERalpha increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0119.
    PubMed     Abstract available


  114. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
    Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
    PubMed     Abstract available


    April 2018
  115. BHARTI R, Dey G, Das AK, Mandal M, et al
    Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0078.
    PubMed     Abstract available


  116. ORECCHIONI S, Talarico G, Labanca V, Calleri A, et al
    Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0076.
    PubMed     Abstract available


  117. LIIKANEN JS, Leidenius MH, Joensuu H, Vironen JH, et al
    Prognostic value of isolated tumour cells in sentinel lymph nodes in early-stage breast cancer: a prospective study.
    Br J Cancer. 2018 Apr 24. pii: 10.1038/s41416-018-0052.
    PubMed     Abstract available


    March 2018
  118. JOSEPH C, Macnamara O, Craze M, Russell R, et al
    Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Br J Cancer. 2018 Mar 28. pii: 10.1038/s41416-018-0041.
    PubMed     Abstract available


  119. QUIROS-GONZALEZ I, Tomaszewski MR, Aitken SJ, Ansel-Bollepalli L, et al
    Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry.
    Br J Cancer. 2018 Mar 26. pii: 10.1038/s41416-018-0033.
    PubMed     Abstract available


  120. MCNAMARA KM, Guestini F, Sauer T, Touma J, et al
    In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics.
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0034.
    PubMed     Abstract available


  121. GYORFFY B, Pongor L, Bottai G, Li X, et al
    An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0030.
    PubMed     Abstract available


  122. EL ANSARI R, Craze ML, Diez-Rodriguez M, Nolan CC, et al
    The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
    Br J Cancer. 2018 Mar 16. pii: 10.1038/s41416-018-0038.
    PubMed     Abstract available


  123. SAUERBREI W, Haeussler T
    Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0023.
    PubMed    


  124. POUJADE FA, Mannion A, Brittain N, Theodosi A, et al
    WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0056.
    PubMed     Abstract available


  125. PAPADAKIS ES, Reeves T, Robson NH, Maishman T, et al
    Reply to 'Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses''.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0032.
    PubMed    


    February 2018
  126. REMSIK J, Fedr R, Navratil J, Bino L, et al
    Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.
    Br J Cancer. 2018 Feb 20. pii: bjc2017497. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  127. DOSS M
    Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure'.
    Br J Cancer. 2018 Feb 13. pii: bjc2017481. doi: 10.1038/bjc.2017.
    PubMed    


  128. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    Reply to 'Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure''.
    Br J Cancer. 2018 Feb 13. pii: bjc2017490. doi: 10.1038/bjc.2017.
    PubMed    


    January 2018
  129. LEGLER K, Rosprim R, Karius T, Eylmann K, et al
    Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017472. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  130. FOUKAKIS T, Lovrot J, Matikas A, Zerdes I, et al
    Immune gene expression and response to chemotherapy in advanced breast cancer.
    Br J Cancer. 2018 Jan 25. pii: bjc2017446. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  131. PLYM A, Bower H, Fredriksson I, Holmberg L, et al
    Loss in working years after a breast cancer diagnosis.
    Br J Cancer. 2018 Jan 23. pii: bjc2017456. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  132. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
    Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
    Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  133. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.
    Br J Cancer. 2018 Jan 23. pii: bjc2017359. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  134. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
    Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017437. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    December 2017
  135. REDDY SM, Barcenas CH, Sinha AK, Hsu L, et al
    Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
    Br J Cancer. 2017 Dec 12. pii: bjc2017379. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    November 2017
  136. CRAZE ML, Cheung H, Jewa N, Coimbra NDM, et al
    MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
    Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  137. NANDY SB, Orozco A, Lopez-Valdez R, Roberts R, et al
    Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis.
    Br J Cancer. 2017;117:1665-1675.
    PubMed     Abstract available


  138. DANIELS B, Kiely BE, Houssami N, Lord SJ, et al
    Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    October 2017
  139. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Abstract available


  140. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    September 2017
  141. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Abstract available


  142. PONZETTI M, Capulli M, Angelucci A, Ventura L, et al
    Non-conventional role of haemoglobin beta in breast malignancy.
    Br J Cancer. 2017;117:994-1006.
    PubMed     Abstract available


  143. MORRELL S, Roder D, Taylor R
    Reply to 'Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study''.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    PubMed    


  144. GREGOIRE C, Bragard I, Jerusalem G, Etienne AM, et al
    Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  145. YE ZJ, Qiu HZ, Liang MZ, Liu ML, et al
    Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  146. OSAKO T, Iwase T, Ushijima M, Yonekura R, et al
    A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  147. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Abstract available


    August 2017
  148. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: